Oncology

This study showed the importance of a multidisciplinary team’s expertise to investigate a clinical inquiry beyond the scope of the clinicians’ skillset and their access to necessary technology.

There was no statistically significant difference between Lovenox (Sanofi–Aventis Pharmaceuticals, France) and biosimilar enoxaparin in the occurrence of post-operative thrombosis for digestive cancer.

Investigators found that those who used statins post-breast cancer diagnosis had a lower risk of breast cancer death when the median total cholesterol decreased.

The investigators advise that the use of bendamustine should be avoided when possible in patients with refractory LBCL who are potential candidates for CAR T-cell therapy.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.

From newsworthy moments to groundbreaking research, these were the most-read oncology-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most watched videos on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most-read reimbursement-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read skin cancer-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.

The CAR T-cell therapy improved relative overall survival by more than a third compared to standard of care.

Expert discusses positive, real-world findings from a claims-based study looking at this therapeutic.

The therapy sustained IDFS benefit compared with ET alone.

The investigators note that psilocybin’s effectiveness in treating depressive symptoms and the positive reception among patients with cancer are encouraging continued research.

The biosimilars landscape is set to witness significant growth, particularly in therapeutic areas like ophthalmology and immunology, with a focus on blockbuster biologics like Humira, Stelara, and Eylea.

The results confirm tebentafusp as a standard of care.

Investigators will evaluate prophylactic tocilizumab prior to treatment with teclistamab.

Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.

The results support perioperative nivolumab as a potential new treatment option.

The CMS FAQ ruling is resulting in barriers to care for patients.

Treatment options can be limited for this patient population.

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.

There is a prognostic impact of clinical and immunohistochemistry markers.

The approval marks the first for an alternative to platinum-containing chemotherapy.

Although treatment is effective, AEs remain difficult for patients.